Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)

NCT02605642 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02605642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 10, 2015
Completion date
December 31, 2018
Enrollment
351 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, rheumatoid diseases